ClinicalTrials.gg
CompletedNCT00069459Updated Sep 25, 2017

Seasonal Affective Depression (SAD) Study

A Phase 1 interventional study of Extended-release Bupropion Hydrochloride in Depressive Disorder, sponsored by GlaxoSmithKline. Completed at 48 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-25.

Primary conditionSeasonal Affective DisorderRegistry: Depressive DisorderReclassifiedWhy we changed it
Registry
Depressive Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Seasonal Affective Disorder
Why
  1. The study's title name Seasonal Affective Disorder, a narrower term within Depressive Disorder.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Seasonal Affective Disorder with a site in United States — none open to participants now, none under way, none of them phase 3. Seasonal Affective Disorder · United States.

Enrollment
2nd of 15
250 · median 61
Started
2003
the only one that year
Phase 1
2 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
3 of 18
GlaxoSmithKline

Among the 18 studies in Seasonal Affective Disorder with a site in United States, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 1, and was the 6th registered.

Seasonal Affective Disorder

31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.

Browse Seasonal Affective Disorder studies →

Open to participants now

None of the 18 studies in Seasonal Affective Disorder with a site in United States is open now. The open studies under Seasonal Affective Disorder, anywhere →

Who these studies take

Of the 1 Seasonal Affective Disorder study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Seasonal Affective Disorder with a site in United States as a file.
02

Study summary

A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder

Read the detailed description

A 7-Month Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase

03

Conditions studied

  • Depressive Disorder

Browse trials for

Keywords

  • Winter depression, winter blues, depression, seasonal depression, seasonal affective disorder
04

In context

Seasonal Affective Disorder Reclassified

31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.

This study's enrollment of 250 is above the median of 60 across 25 interventional studies indexed under Seasonal Affective Disorder.

Browse Seasonal Affective Disorder studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Seasonal Affective Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of seizure disorder or brain injury.
  • History or current diagnosis of anorexia nervosa or bulimia.
  • Recurrent summer depression more frequently than winter depression.
  • Primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Post-traumatic Stress Disorder(PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
  • Initiated psychotherapy within the last 3 months.
06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Other
    Extended-release Bupropion Hydrochloride

    Extended-release Bupropion Hydrochloride

    Drug: Extended-release Bupropion Hydrochloride

Interventions

  • Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride

07

What researchers measure

Primary outcomes

  1. End of season depression-free rate.

    Time frame: 7 months

Secondary outcomes

  1. Time to onset of a seasonal depressive episode.Change from randomization on SIGH-SAD and HAMD-17.

    Time frame: 7 months

08

Study locations

48 sites
  • GSK Investigational Site
    Anchorage, Alaska 99508, United States
  • GSK Investigational Site
    Hamden, Connecticut 06518, United States
  • GSK Investigational Site
    Newark, Delaware 19713, United States
  • GSK Investigational Site
    Wilmington, Delaware 19808, United States
  • GSK Investigational Site
    Washington, D.C., District of Columbia 20016, United States
  • GSK Investigational Site
    Boise, Idaho 83702, United States
  • GSK Investigational Site
    Edwardsville, Illinois 62025, United States
  • GSK Investigational Site
    Hoffman Estates, Illinois 60194, United States
  • GSK Investigational Site
    Northfield, Illinois 60093, United States
  • GSK Investigational Site
    Oak Brook, Illinois 60523, United States
  • GSK Investigational Site
    Oakbrook Terrace, Illinois 60181, United States
  • GSK Investigational Site
    Cedar Rapids, Iowa 52401, United States
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
  • GSK Investigational Site
    Baltimore, Maryland 21204, United States
  • GSK Investigational Site
    Rockville, Maryland 20852, United States
  • GSK Investigational Site
    Belmont, Massachusetts 02478, United States
  • GSK Investigational Site
    Farmington Hills, Michigan 48334, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63108, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    Kenilworth, New Jersey 07033, United States
  • GSK Investigational Site
    Moorestown, New Jersey 08057, United States
  • GSK Investigational Site
    Piscataway, New Jersey 08854, United States
  • GSK Investigational Site
    Princeton, New Jersey 08540, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Lawrence, New York 11559, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    New York, New York 10128, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Lyndhurst, Ohio 44124, United States
  • GSK Investigational Site
    Toledo, Ohio 43623, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Portland, Oregon 97201, United States
  • GSK Investigational Site
    Portland, Oregon 97209, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18104, United States
  • GSK Investigational Site
    Havertown, Pennsylvania 19083, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • GSK Investigational Site
    Lincoln, Rhode Island 02865-4208, United States
  • GSK Investigational Site
    Woodstock, Vermont 05091, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Brown Deer, Wisconsin 53223, United States
  • GSK Investigational Site
    Madison, Wisconsin 53719, United States
  • GSK Investigational Site
    Menomonee Falls, Wisconsin 53051, United States
  • GSK Investigational Site
    Middleton, Wisconsin 53562-2215, United States
09

References and documents

Publications

  • Modell, JG, Rosenthal NE. Once-Daily Bupropion XL for the prevention of seasonal major depressive episodes. 43nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12-16 December, 2004.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2003 to primary completion in Jun 2004, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2003
First posted
Sep 26, 2003
StartActual
Sep 23, 2003
Primary completionActual
Jun 3, 2004
CompletionActual
Jun 3, 2004
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00069459
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 26, 2003
Start date
Sep 23, 2003
Primary completion
Jun 3, 2004
Completion
Jun 3, 2004
Last update
Sep 25, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion